Drug
Cabiralizumab
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Group | anti-CSF1R mAb |
| Mechanism of Action | anti-CSF1R antibody |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Immunologically synergistic in principle (reprograms suppressive TAMs/MDSCs post-RT), not a DNA-level sensitizer (Shang et al. Frontiers Immununology 2024; Sanseviero et al. Nature Cancer 2026). No in-field DNA sensitization; class-specific effects (periorbital edema, hepatic/CK elevations) rather than radiation-side-effects potentiation are the main concern.
Data on this page refer exclusively to patients treated with
Cabiralizumab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
anti-CSF1R mAb group page.